Printer Friendly
The Free Library
14,651,959 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

qRT-PCR Technologies Emerge as the Fastest Growing Segment in the U.S. Genomics Market.


DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c50664) has announced the addition of the Frost & Sullivan report: Strategic Analysis of U.S. Genomics Markets to their offering.

This research service provides a strategic analysis of genomics markets within the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The market was divided into the total U.S. nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis.  isolation markets, total U.S. PCR PCR polymerase chain reaction.

PCR
abbr.
polymerase chain reaction


Polymerase chain reaction (PCR) 
 markets, total U.S. qRT-PCR markets, total U.S. DNA microarray DNA microarray

A small solid support, usually a membrane or glass slide, on which sequences of DNA are fixed in an orderly arrangement. DNA microarrays are used for rapid surveys of the expression of many genes simultaneously, as the sequences contained on a
 markets, and total U.S. DNA sequencing technology markets. Each segment covers market trends, technology trends, competitive structure, market share analysis, and revenue forecasts. The key challenges and strategies are covered for the total market overview.

Next Generation Genomics Technologies Providing Fresh Impetus

While the days of high market growth, driven by the human genome project, are behind us, the era of personal genomics is yet to come. However, the realization of personal genomics is being hindered by genomics platforms that are too inefficient and expensive for ultra-high throughput comprehensive genome-wide analyses. Consequently, markets for last-generation genomics technologies, such as general polymerase chain reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is  (PCR) and conventional deoxyribonucleic acid (DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
) sequencing, are beginning to stabilize. Concurrently, next generation genomics technologies are breathing new life into the market, and are expected to contribute a compound annual growth rate (CAGR CAGR

See: Compound Annual Growth Rate
) of 10.4 percent between 2005 and 2012.

However, high instrument costs continue to be a major barrier for market growth. High instrument costs often result in a centralized installed base, which challenges market participants that hope to grow instrument-driven revenue generation. Moreover, receiving Federal Drug Administration (FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
) approval is another challenge for market participants that want to enter the clinical diagnostics market. "The uncertain path to personalized genomics often complicates competitive strategies," notes the analyst of this research service. "Vendors will have to formulate strategies with an appreciation for the evolving aims of genomics research and also maintain a broad value proposition with relation to discovery, validation, and commercialization."

qRT-PCR Technologies Emerge as the Fastest Growing Segment

Among the market segments, quantitative reverse transcriptase Reverse transcriptase

Any of the deoxyribonucleic acid (DNA) polymerases present in particles of retroviruses which are able to carry out DNA synthesis using an RNA template.
 (qRT)-PCR technology, including instrumentation and reagents, is developing as the fastest growing segment of the total U.S. genomics market. As researchers attempt to validate discoveries made on the foundation of The Human Genome Project, they find technologies such as qRT-PCR ideal for their targeted studies. Following the qRT-PCR segment, DNA microarray technology is developing as the second-fastest growing segment of the total U.S. genomics market. While genome-wide expression analyses are forecasted to drive the majority of DNA microarray segment growth, markets related to novel genomics analyses, such as comparative genomic hybridization hybridization /hy·brid·iza·tion/ (hi?brid-i-za´shun)
1. crossbreeding; the act or process of producing hybrids.

2. molecular hybridization

3.
 (CGH CGH Comparative Genomic Hybridization
CGH Changi General Hospital (Singapore)
CGH Computer-Generated Hologram
CGH Community General Hospital (Syracuse, NY) 
), genome-wide methylation methylation,
n a phase-II detoxification pathway in the liver; methyl groups combine with toxins to rid the body of various substances.

methylation
(meth´
 studies, and chromatin immunoprecipitation (ChIP)-chip, are likely to see the highest growth. Finally, the majority of the DNA sequencing technology segment growth is anticipated to result from the introduction and extensive placement of next generation DNA sequencing technologies.

With respect to the market structure, there are approximately 150 companies that participate in the total U.S. genomics market. Market participants include well-established life science supply companies, medium-sized companies that focus exclusively on market segments, and small, niche companies. "Top industry participants are successfully developing specific applications for each evolutionary stage of the genomics market," says the analyst. "Leading companies are likely to maintain revenue streams, while strategically positioning themselves for the significant penetration of future markets for clinical applications of genomic technologies."

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

By Application:

-U.S. nucleic acid isolation markets

-U.S. PCR markets

-U.S. qRT-PCR markets

-U.S. DNA microarray markets

-U.S. DNA sequencing technology markets

-Key end-user groups

Topics Covered

1 Introduction

2 Executive Summary

3 Total U.S. Genomics Markets

4 U.S. Nucleic Acid Isolation Markets

5 U.S. Pcr Markets

6 U.S. Qrt-Pcr Markets

7 U.S. DNA Microarrays Markets

8 U.S. DNA Sequencing Technologies Markets

9 Decision Support Database

For more information visit http://www.researchandmarkets.com/reports/c50664
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 19, 2007
Words:657
Previous Article:Examine the Amount and the Type of Antistatics Used in Processing Methods.
Next Article:Healthcare Providers' Need for Single Point of Contact is Driving the Market for HIT Platforms.
Topics:



Related Articles
The danger of extrapolation: humans and rodents differ in response to PCBs.(Science Selections)
Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression.(Genomics and Risk...
Quantitative PCR deconstruction of discrepancies between results reported by different hybridization platforms.(Genomics and Risk Assessment:...
Identification of platform-independent gene expression markers of cisplatin nephrotoxicity.(Genomics and Risk Assessment: Mini-Monograph)
Road worthy: auto recyclers remain competitive as suppliers of components harvested from salvaged vehicles.(Auto Recycling Update)
QIAGEN LAUNCHES PRODUCT PORTFOLIO FOR RNAI/SYBR RT-PCR.
SARs coronavirus detection methods.(DISPATCHES)(Severe acute respiratory syndrome)
ORION/UNIVERSITY OF GLASGOW TO IDENTIFY EPIGENETIC BIOMARKERS.
QIAGEN UNVEILS FAST CYCLING PCR TECHNOLOGY.
Takara Bio Grants Transgenomic License for LA-PCR Technology.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles